# GRAIL Inc. Common Stock (GRAL) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $80.34, market value $3.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). GRAIL Inc. Common Stock reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 21.7×**. Each dollar of revenue is priced at 21.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -8.3%** (5-yr avg -55.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -338.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -277.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: -15.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -13.4%**. Each dollar of assets produces -13.4% of profit.

## Growth
- **Revenue growth (1 yr): 17.2%** (3-yr 38.4%/yr). Revenue grew 17.2% over the last year.
- **EPS growth (1 yr): 82.5%**. Earnings per share rose 82.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 11.97** (quick 11.97). Current assets cover the next year's liabilities 11.97 times.
- **Altman Z-score: 7.27**. A Z-score of 7.27 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. GRAIL Inc. Common Stock does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover GRAIL Inc. Common Stock; the consensus is buy, with an average price target of $72.38 (-10% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 139.2%** (YTD -6.1%, 3-mo 33.9%). The shares are up 139.2% over twelve months including dividends.
- **From 52-week high: -32.4%** (127.0% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 2.66** (volatility 100%). Beta of 2.66 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GRAL · Page: https://foliofundamentals.com/stocks/gral

Not investment advice.